Index to Volume 21

Author Index

- A -

Abramowitz W: see Gutierrez M, et al, 163
ACCP 2001 Annual Meeting—Abstracts and Index of Authors, 1253
ACCP 2001 Spring Practice and Research Forum—Abstracts and Index of Authors, 365
Adam RD: see Zhu M, et al, 891
Addesse E: see Kane MP, et al, 1473
Adkison JD, Konzem SL: Management of Acute Exacerbations of Chronic Obstructive Pulmonary Disease, 929
Akbari S: see Spruill WJ, et al, 1407
Akhras KS: see Ross SD, et al, 940
Aldridge MA, Ito MK: Fenofibrate and Warfarin Interaction, 886
Allen DD, Bond CA: Prepharmacy Predictors of Success in Pharmacy School: Grade Point Averages, Pharmacy College Admissions Test, Communication Abilities, and Critical Thinking Skills, 842
Allen DD: see Rojas-Fernandez CH, et al, 74
Amato CM: see Hilleman DE, et al, 1415
Amato MG: see Okano GJ, et al, 1123
Ammar R, Song JC, Kluger J, White CM: Evaluation of Electrocardiographic and Hemodynamic Effects of Caffeine with Acute Dosing in Healthy Volunteers, 437
Anderson D: see MacLaren R, et al, 175
Anstead MI: see Robinson CA, et al, 1320
Arguelles L: see Gandhi SK, et al, 684
Armstrong EP, Patrick KL, Erstad BL: Comparison of Preoperative Skin Preparation Products, 345
Ashby CL: see Hilleman DE, et al, 1415
Asmus MJ, Milavetz G, Tice AL, Teresi ME: In Vitro Characteristics of Tobramycin Aerosol from Ultrasonic and Jet Nebulizers, 534
AZL10002 Study Group: see Crémieux A, et al, 424

- B -

Bakst G: see Kane MP, et al, 1473
Banevicius MA: see Nicolau DP, et al, 275
Banh HL: see Sirmans SM, et al, 513
Barbour MM: see Derby CA, et al, 676
Bauman JL: see Hilleman DE, et al, 556
Bauman JL: see Schoen MD, et al, 1455
Bearden DT, Danziger LH: Mechanism of Action of and Resistance to Quinolones, 224S
Bearden DT, Neuhauser MM, Garey KW: Telithromycin: An Oral Ketolide for Respiratory Infections, 1204
Bechara CI, Goldman-Levine JD: Dramatic Worsening of Type 2 Diabetes Mellitus Due to Olanzapine After 3 Years of Therapy, 1444
Beck JK: see Sirmans SM, et al, 513
Bell DM: Markers for Progression of Coronary Disease, 190S
Berenson CS: see Chitre MM, et al, 493
Berger MS: see Korth-Bradley JM, et al, 1175
Berning SE: see Zhu M, et al, 1037
Bertin RJ: see Wells BG, et al, 126
Bertino JS Jr: Integrating Fluoroquinolones into the Hospital Formulary, 273S
Bertino JS Jr: see Streetman DS, et al, 443
Biggs C: see Simpson SH, et al, 731
Biggs RS: see Simpson SH, et al, 731
Billups SJ: see Okano GJ, et al, 1123
Birnbaum AK, Kriel RL, Im Y, Remmel RP: Relative Bioavailability of Lamotrigine Chewable Dispersible Tablets Administered Rectally, 158
Birner AM, Meyer LP: Photosensitivity Associated with Fluorouracil, Prochlorperazine, and Topical Tretinoin, 258
Birrell C: see Zussman BD, et al, 653
Blake KV: Drug Treatment of Airway Inflammation in Asthma, 3S
Blanchard N, Kyllonen K: Introduction to New Strides in Asthma, 1S
Bleske BE, Song J, Chow MSS, Kluger J, White CM: Hematologic and Chemical Changes Observed during and after Cardiac Arrest in a Canine Model—A Pilot Study, 1187
Bompart F: see Linden PK, et al, 661
Bond CA, Raehl CL, Franke T: Interrelationships among Mortality Rates, Drug Costs, Total Cost of Care, and Length of Stay in United States Hospitals: Summary and Recommendations for Clinical Pharmacy Services and Staffing, 129
Bond CA, Raehl CL, Franke T: Medication Errors in United States Hospitals, 1023
Bond CA, Raehl CL: Pharmacists' Assessment of Dispensing Errors: Risk Factors, Practice Sites, Professional Functions, and Satisfaction, 614
Bond CA: see Allen DD, et al, 842
Boumpas DT: see Kuo GM, et al, 528
Bowles TM, Sommi RW, Mohsen A: Successful Management of Prolonged γ-Hydroxybutyrate and Alcohol Withdrawal, 254
Boyer JG: see Gandhi SK, et al, 684
Brady MT: see Temple ME, et al, 351
Branch RA: see Conley EL, et al, 1325
Brandl KM, Langley KA, Riker RR, Dork LA, Qualls CR, Levy H: Confirming the Reliability of the Sedation-Agitation Scale Administered by ICU Nurses without Experience in Its Use, 431
Brophy DF, Wazny LD, Gehr TWB, Comstock TJ,

Venitz J: The Pharmacokinetics of Subcutaneous Enoxaparin in End-Stage Renal Disease, 169
Brouwer KLR: see Matheny CJ, et al, 778
Bunch TH: see Garey KW, et al, 855
Bungard TJ: see Olson KL, et al, 807
Bungard TJ: see Tsuyuki RT, et al, 576
Burgess DS: see Nathisuwan S, et al, 920
Burman WJ: see Zhu M, et al, 1037
Burstein AH, Reed E, Tompkins AC, Venzon D, Figg WD: Phenylacetate Pharmacokinetics Based on Iterative Two-Stage Population Analysis, 281
Burstein AH: see Kuo GM, et al, 528
Busch RS: see Kane MP, et al, 1473

- C -

Cafiero AC: see Giles JT, et al, 243
Campbell A: see MacLaren R, et al, 175
Cannon JP, Garey KW, Danziger LH: A Prospective and Retrospective Analysis of the Nephrotoxicity and Efficacy of Lipid-Based Amphotericin B Formulations, 1107
Carlson MK, Gleason PP, Sen S: Elevation of Hepatic Transaminases after Enoxaparin Use: Case Report and Review of Unfractionated and Low Molecular-Weight Heparin-Induced Hepatotoxicity, 108
Carmichael J: see Okano GJ, et al, 1123
Carnahan RM, Lund BC, Perry PJ: Ziprasidone, a New Atypical Antipsychotic Drug, 717
Caron MF, White CM: Evaluation of the Antihyperlipidemic Properties of Dietary Supplements, 481
Carr A: see Zussman BD, et al, 653
Carter BL: see Okano GJ, et al, 1123
Cash J: see Lugo RA, et al, 1566
Caulfield JS: see Miller LG, et al, 770
Cawley MJ: Short-Term Lorazepam Infusion and Concern for Propylene Glycol Toxicity: Case Report and Review, 1140
Chapman SA, Wacksman GP, Patterson BD: Pancreatitis Associated with Valproic Acid: A Review of the Literature, 1549
Chapman SW: see Cleary JD, et al, 1046
Cheng JWM, Kalis MM, Feifer S: Patient-Reported Adherence to Guidelines of the Sixth Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, 828
Chesrown S: see Sherman J, et al, 1464
Childs JM: see Zhu M, et al, 891
Chin TWF: see Miller LG, et al, 770
Chitre MM, Berenson CS: Idiosyncratic Rifabutin-Induced Leukopenia and SIADH: Case Report and Review, 493
Chow M: see White CM, et al, 773
Chow MSS: see Bleske BE, et al, 1187
Chrousos GP: see McGriff NJ, et al, 1425
Church CO: see Thompson DF, et al, 1364
Circiumaru I: see Iannini PB, et al, 361
Clark DJ: see Zussman BD, et al, 653
Clarke SH: see Sherman DS, et al, 1167
Cleary JD, Rogers PD, Chapman SW: Differential Transcription Factor Expression in Human Mononuclear Cells in Response to Amphotericin B: Identification with Complementary DNA Microarray Technology, 1046
Clement KD: see Foss MT, et al, 1422
Cobb HH III: see Spruill WJ, et al, 1407
Cole E: see Glover ML, et al, 7
Coley KC: see Conley EL, et al, 1325
Comstock TJ: see Brophy DF, et al, 169
Conley EL, Coley KC, Pollock BG, DaPos SV, Maxwell R, Branch RA: Prevalence and Risk of Thrombocytopenia with Valproic Acid: Experience at a Psychiatric Teaching Hospital, 1325
Connor SE: see Schoen MD, et al, 1455
Cooper SL: see Straka RJ, et al, 818
Cordina M, McElnay JC, Hughes CM: Assessment of a Community Pharmacy-Based Program for Patients with Asthma, 1196
Cormier J: see Lambert J, et al, 509
Covey D: see Okano GJ, et al, 1123
Cox CD: see Tsikouris JP, et al, 1514
Craigmyle LJ: see Robinson CA, et al, 1320
Creed PL: Antithrombotic Drugs for Secondary Stroke Prophylaxis, 452
Crémieux A, Katlama C, Gillotin C, Demarles D, Yuen GJ, Raffi F, AZL10002 Study Group: A Comparison of the Steady-State Pharmacokinetics and Safety of Abacavir, Lamivudine, and Zidovudine Taken as a Triple Combination Tablet and as Abacavir plus a Lamivudine-Zidovudine Double Combination Tablet by HIV-1-Infected Adults, 424
Crouch CW: see Li Z, et al, 263
Csako G: see McGriff NJ, et al, 1425
Cushman M: see Possidente CJ, et al, 295
Cuthrell C: see Glover ML, et al, 7

- D -

da Silva O: see Zaw W, et al, 642
Danziger LH: Introduction to Quinolones in the Hospital Setting, 223S
Danziger LH: see Bearden DT, et al, 224S
Danziger LH: see Cannon JP, et al, 1107
DaPos SV: see Conley EL, et al, 1325
Darkow T, Gora-Harper ML, Goulson DT, Record KE: Impact of Antiemetic Selection on Postoperative Nausea and Vomiting and Patient Satisfaction, 540
Davie CC: see Zussman BD, et al, 653
Davies NM, Longstreth J, Jamali F: Misoprostol Therapeutics Revisited, 60
Davydov L: see Spinler SA, et al, 363
Dedhiya SD: see Ernst ME, et al, 988
Demarles D: see Crémieux A, et al, 424
Derby CA, Barbour MM, Hume AL, McKinlay JB: Drug Therapy and Prevalence of Erectile Dysfunction in the Massachusetts Male Aging Study Cohort, 676
Desai NS: see Gerk PM, et al, 669
Destache CJ: see Faulkner MA, et al, 1055
Destache CJ: see Streetman DS, et al, 443
DeVane CL: Substance P: A New Era, a New Role,

1061
Devlin JW, Tyburski JG, Moed B: Implementation and Evaluation of Guidelines for Use of Enoxaparin as Deep Vein Thrombosis Prophylaxis after Major Trauma, 740
Devlin JW: see Kanji S, et al, 1389
DiCenzo RC: see Haas CE, et al, 1192
DiDomenico RJ: see Schoen MD, et al, 1455
Diep L: see McGriff NJ, et al, 1425
Dietz PA: see Spinler SA, et al, 363
Dischler JE: see Schoen MD, et al, 1455
Dombrowski R: see Okano GJ, et al, 1123
Donaldson AR: see Taylor CT, et al, 488
Doraiswamy PM: see Seaburg HL, et al, 1448
Dork LA: see Brandl KM, et al, 431
Doucette WR: see Ernst ME, et al, 988
Dowell JA: see Korth-Bradley JM, et al, 1175
Dunn EC: see Giles JT, et al, 243
Duplaga BA, Rivers CW, Nutescu E: Dosing and Monitoring of Low-Molecular-Weight Heparins in Special Populations, 218

- E -

Easton-Carter KL, Hardikar W, Smith AL: Possible Roxithromycin-Induced Fulminant Hepatic Failure in a Child, 867
Elenbaas RM: ACCP Manpower White Paper, Introduction to Commentaries, 116
Emerson JF: see Jafari M, et al, 1403
Ensom MHH: see Levine M, et al, 405
Ernst EJ: Investigational Antifungal Agents, 165S
Ernst ME, Doucette WR, Dedhiya SD, Osterhaus MC, Kumbera PA, Osterhaus JT, Townsend RJ: Use of Point-of-Service Health Status Assessments by Community Pharmacists to Identify and Resolve Drug-Related Problems in Patients with Musculoskeletal Disorders, 988
Erstad BL: see Armstrong EP, et al, 345
Etminan M: Quantifying the Interaction between Angiotensin-Converting Enzyme Inhibitors and Aspirin: Are We Using the Right Method, 1247

- F -

Fan C: see White CM, et al, 773
Farris KB: see Simpson SH, et al, 731
Faulkner MA, Hilleman DE, Destache CJ, Mooss AN: Potential Influence of Timing of Low-Density Lipoprotein Cholesterol Evaluation in Patients with Acute Coronary Syndrome, 1055
Feagan BG: A Controlled Trial of a Critical Pathway for Treating Community-Acquired Pneumonia: The CAPITAL Study, 89S
Feifer S: see Cheng JWM, et al, 828
Ferko N, Levine MAH: Evaluation of the Association Between St. John's Wort and Elevated Thyroid-Stimulating Hormone, 1574
Figg WD: see Burstein AH, et al, 281
Fish D: see Page RL II, et al, 1436
Fish DN, North DS: Gatifloxacin, an Advanced 8-Methoxy Fluoroquinolone, 35
Fish DN: Fluoroquinolone Adverse Effects and Drug Interactions, 253S
Fogel J: Post Hoc Power Analysis—Another View, 1150
Foss MT, Clement KD: Metformin as a Cause of Late-Onset Chronic Diarrhea, 1422
Franke T: see Bond CA, et al, 1023
Franke T: see Bond CA, et al, 129
Fraser GL, Riker RR, Prato BS, Wilkins ML: The Frequency and Cost of Patient-Initiated Device Removal in the ICU, 1
Freels SA: see Kraus DM, et al, 416
Freeman DA: see Sirmans SM, et al, 513
Frothingham R: Rates of Torsades de Pointes Associated with Ciprofloxacin, Ofloxacin, Levofloxacin, Gatifloxacin, and Moxifloxacin, 1468

- G -

Gaffney BJ: see Noviasky JA, et al, 1250
Gal P: see Glover ML, et al, 7
Gandhi SK, Arguelles L, Boyer JG: Economic Impact of Neutropenia and Febrile Neutropenia in Breast Cancer: Estimates from Two National Databases, 684
Gans JA, Maine LL: American Pharmaceutical Association View on ACCP Manpower White Paper, 120
Garey KW, Pendland SL, Huynh VT, Bunch TH, Jensen GM, Pursell KJ: *Cunninghamella bertholletiae* Infection in a Bone Marrow Transplant Patient: Amphotericin Lung Penetration, MIC Determinations, and Review of the Literature, 855
Garey KW, Tesoro E, Muggia V, Pasquier O, Rodvold KA: Cerebrospinal Fluid Concentrations of Quinupristin-Dalfopristin in a Patient with Vancomycin-Resistant *Enterococcus faecium* Ventriculitis, 748
Garey KW: see Bearden DT, et al, 1204
Garey KW: see Cannon JP, et al, 1107
Garnett WR: Clinical Implications of Drug Interactions with Coxibs, 1223
Gattis WA: Metoprolol CR/XL in the Treatment of Chronic Heart Failure, 604
Gaul BL: see Hoehns JD, et al, 871
Gehr TWB: see Brophy DF, et al, 169
Gehrs KM: Visual Disturbance Associated with Celecoxib— A Comment, 1014
Gentile TC: see Smith AL, et al, 764
Geraets DR: see Hoehns JD, et al, 871
Geraets DR: see Okano GJ, et al, 1123
Gerk PM, Kuhn RJ, Desai NS, McNamara PJ: Active Transport of Nitrofurantoin into Human Milk, 669
Gibbs H: see Taylor AJ, et al, 1130
Giles JT, Kennedy DT, Dunn EC, Wallace WL, Meadows SL, Cafiero AC: Results of a Community Pharmacy-Based Breast Cancer Risk-Assessment and Education Program, 243
Giles JT: see Tran MT, et al, 797
Gillotin C: see Crémieux A, et al, 424
Glauser TA: Oxcarbazepine in the Treatment of

Epilepsy, 904
Gleason PP: see Carlson MK, et al, 108
Glick HA: see Li Z, et al, 263
Glover ML, Shaffer CL, Rubino CM, Cuthrell C, Schoening S, Cole E, Potter D, Ransom JL, Gal P: A Multicenter Evaluation of Gentamicin Therapy in the Neonatal Intensive Care Unit, 7
Golding M: see Kotlyar M, et al, 1530
Goldman-Levine JD: see Bechara CI, et al, 1444
Gora-Harper ML: see Darkow T, et al, 540
Goram AL, Richmond PL: Pegylated Liposomal Doxorubicin: Tolerability and Toxicity, 751
Goulson DT: see Darkow T, et al, 540
Grace K: see Taylor AJ, et al, 1130
Graham KK: see Mangum EM, 1352
Gray S: see Linden PK, et al, 661
Greenberg LE, Nguyen T, Miller SM: Suspected Allopurinol-Induced Aseptic Meningitis, 1007
Groll AH, Piscitelli SC, Walsh TJ: Antifungal Pharmacodynamics: Concentration-Effect Relationships in Vitro and in Vivo, 133S
Guay DRP: Adjunctive Agents in the Management of Chronic Pain, 1070
Gunderson BW, Ross GH, Ibrahim KH, Rotschafer JC: What Do We Really Know About Antibiotic Pharmacodynamics, 302S
Guthrie K: see Okano GJ, et al, 1123
Guthrie SK: see Teter CJ, et al, 1486
Gutierrez M, Abramowitz W: Lack of Effect of a Single Dose of Ketoconazole on the Pharmacokinetics of Citalopram, 163

- H -

Haas CE, Kaufman DC, DiCenzo RC: Effects of Metronidazole on Hepatic CYP3A4 Activity, 1192
Haase KK, Lapointe M, Haines SJ: Aseptic Meningitis after Intraventricular Administration of Gentamicin, 103
Hafkin B: see Li Z, et al, 263
Haider K: see Smith AL, et al, 764
Haines SJ: see Haase KK, et al, 103
Haines ST: Introduction to Low-Molecular-Weight Heparins for Venous Thromboembolism: Making and Evidence-Based Treatment Choice, 49S
Hamilton RA: see Kane MP, et al, 1473
Handley DA: Single-Isomer β-Agonists, 21S
Hannon PR: see Kraus DM, et al, 416
Hansen DB: Antithrombotic Drugs for Secondary Stroke Prophylaxis—A Comment, 1020
Hardikar W: see Easton-Carter KL, et al, 867
Harris IM: see Miller LG, et al, 770
Hatch CD, Lund BC, Perry PJ: Failed Challenge with Quetiapine after Neuroleptic Malignant Syndrome with Conventional Antipsychotics, 1003
Hatsukami DK: see Kotlyar M, et al, 1530
Havrda DE, Rathbun S, Scheid D: A Case Report of Warfarin Resistance Due to Azathioprine and Review of the Literature, 355
Hawley JM: see Kim KY, et al, 498
Helmboldt KM: see Lott RS, et al, 1345
Henann NE, Zambie MF: Gatifloxacin-Associated Acute Hepatitis, 1579
Hendeles L: see Sherman J, et al, 1464
Herbel JL: see Sylvia LM, et al, 395
Hilleman DE, Bauman JL: Role of Antiarrhythmic Therapy in Patients at Risk for Sudden Cardiac Death: An Evidence-Based Review, 556
Hilleman DE, Monaghan MS, Ashby CL, Mashni JE, Woolley K, Amato CM: Physician-Prompting Statin Therapy Intervention Improves Outcomes in Patients with Coronary Heart Disease, 1415
Hilleman DE, Wurdeman RL, Lenz TL: Therapeutic Change of HMG-CoA Reductase Inhibitors in Patients with Coronary Artery Disease, 410
Hilleman DE: see Faulkner MA, et al, 1055
Hilleman DE: see Lenz TL, et al, 898
Hobson EH: see Van Amburgh JA, et al, 1115
Hoehns JD, Stanford RH, Geraets DR, Skelly KS, Lee HC, Gaul BL: Torsades de Pointes Associated with Chlorpromazine: Case Report and Review of Associated Ventricular Arrhythmias, 871
Hoffman HL, Pfaller MA: In Vitro Antifungal Susceptibility Testing, 111S
Hovde LB: see Ross GH, et al, 1479
Hovinga CA: Levetiracetam: A Novel Antiepileptic Drug, 1375
Howe JG: see Possidente CJ, et al, 295
Hsu SI: Biopsy-Proved Acute Tubulointerstitial Nephritis and Toxic Epidermal Necrolysis Associated with Vancomycin, 1233
Hughes CM: see Cordina M, et al, 1196
Hughes CM: see VanHaaren AM, et al, 1159
Hume A: see Miller LG, et al, 770
Hume AL: see Derby CA, et al, 676
Hutson A: see Sherman J, et al, 1464
Huynh VT: see Garey KW, et al, 855
Hyatt R: see Taylor AJ, et al, 1130

- I, J -

Iannini PB, Circiumaru I: Gatifloxacin-Induced QTc Prolongation and Ventricular Tachycardia, 361
Iannini PB, Tillotson GS: Evaluating the Risk of Cardiac Toxicity, 261
Ibrahim KH: see Gunderson BW, et al, 302S
Ibrahim YH: see Ross GH, et al, 1479
Illei GG: see Kuo GM, et al, 528
Im Y: see Birnbaum AK, et al, 158
Inverso SM, Spinler SA: Antithrombotic Agents for Secondary Prevention of Cardioembolic and Noncardioembolic Stroke—Another Viewpoint, 1021
Inverso SM: see Spinler SA, et al, 691
Ito MK: see Aldridge MA, et al, 886
Jackson EA: see Miller LG, et al, 770
Jafari M, Masih M, Emerson JF: The Value of Pharmacist Involvement in a Point-of-Care Service, Walk-In Lipid Screening Program, 1403
Jamali F: see Davies NM, et al, 60
Jamerson BD: see Kotlyar M, et al, 1530
Jaresko GS: see Zhu M, et al, 1037

Jelliffe RW: see Zhu M, et al, 1037
Jellison TK, McKinnon PS, Rybak MJ: Epidemiology, Resistance, and Outcomes of *Acinetobacter baumannii* Bacteremia Treated with Imipenem-Cilastatin or Ampicillin-Sulbactam, 142
Jensen GM: see Garey KW, et al, 855
Johnson JA: see Simpson SH, et al, 627
Johnson JA: see Simpson SH, et al, 731
Jones MT: see Stoner SC, et al, 850
Jones, DL: see Taylor AJ, et al, 1130
Jue S: see Okano GJ, et al, 1123

- K -

Kabbani M: see McGriff NJ, et al, 1425
Kale-Pradhan PB: see Seta ML, et al, 1181
Kalis MM: see Cheng JWM, et al, 828
Kalus JS, Spencer AP: Enoxaparin Should Be Used Cautiously in Patients with End-Stage Renal Disease, 1015
Kane MP, Hamilton RA, Addesse E, Busch RS, Bakst G: Cholesterol and Glycemic Effects of Niaspan in Patients with Type 2 Diabetes, 1473
Kanga JF: see Robinson CA, et al, 1320
Kanji S, Devlin JW, Piekos KA, Racine E: Recombinant Human Activated Protein C, Drotrecogin Alfa (activated): A Novel Therapy for Severe Sepsis, 1389
Kanmaz TJ: see Miller LG, et al, 770
Katlama C: see Crémieux A, et al, 424
Kauffman JM: Do Hypolipidemic Drugs Lower Medical Expenses, 1583
Kaufman DC: see Haas CE, et al, 1192
Kelly J: see Zussman BD, et al, 653
Kelly WN: Can the Frequency and Risks of Fatal Adverse Drug Events Be Determined, 521
Kennedy DT: see Giles JT, et al, 243
Kennedy DT: see Tran MT, et al, 797
Kennedy MJ: Inflammation and Cystic Fibrosis Pulmonary Disease, 593
Khan MA: see St. Peter JV, et al, 183
Kim KY, Moles JK, Hawley JM: Selective Serotonin Reuptake Inhibitors for Aggressive Behavior in Patients with Dementia after Head Injury, 498
King SP: see Korth-Bradley JM, et al, 1175
Klepser ME: Antifungal Resistance Among *Candida* Species, 124S
Klepser ME: Introduction to New Insights in Medical Mycology: Focus on Fungal Infections, 109S
Kluger J: see Ammar R, et al, 437
Kluger J: see Bleske BE, et al, 1187
Knell M: see Miller LG, et al, 770
Knoppert DC: see Zaw W, et al, 642
Kockler DR, McCarthy MW, Lawson CL: Seizure Activity and Unresponsiveness after Hydroxycut Ingestion, 647
Kontoyiannis DP: A Clinical Perspective for the Management of Invasive Fungal Infections: Focus on IDSA Guidelines, 175S
Kontoyiannis DP: see Lewis RE, et al, 149S
Konzem SL: see Adkison JD, et al, 929
Koranyi KI: see Temple ME, et al, 287
Koranyi KI: see Temple ME, et al, 351
Korth-Bradley JM, Dowell JA, King SP, Liu H, Berger MS, for the Mylotarg Study Group: Impact of Age and Gender on the Pharmacokinetics of Gemtuzumab Ozogamicin, 1175
Kotlyar M, Golding M, Hatsukami DK, Jamerson BD: Effect of Nonnicotine Pharmacotherapy on Smoking Behavior, 1530
Kraus DM, Stohlmeyer LA, Hannon PR, Freels SA: Effectiveness and Infant Acceptance of the Rx Medibottle versus the Oral Syringe , 416
Kriel RL: see Birnbaum AK, et al, 158
Kuhn RJ: see Gerk PM, et al, 669
Kuhn RJ: see Robinson CA, et al, 1320
Kumbera PA: see Ernst ME, et al, 988
Kuntz A: see Simpson SH, et al, 731
Kuo GM, Boumpas DT, Illei GG, Yarboro C, Pucino F, Burstein AH: Fludarabine Pharmacokinetics after Subcutaneous and Intravenous Administration in Patients with Lupus Nephritis, 528
Kuter DJ, Tillotson GS: Hematologic Effects of Antimicrobials: Focus on the Oxazolidinone Linezolid, 1010
Kwa AL, Tam VH, Rybak MJ: *Rhodococcus equi* Pneumonia in a Patient with Human Immunodeficiency Virus: Case Report and Review, 998
Kyllonen K: see Blanchard N, et al, 1S

- L -

Lamarre P, Perreault B, Lesur O: Vasopressin and Blood Pressure Support for Pancreatitis-Induced Systemic Inflammatory Response Syndrome with Circulatory Shock, 506
Lamb MW: see Matheny CJ, et al, 778
Lambert J, Cormier J: Potential Interaction between Warfarin and Boldo-Fenugreek, 509
Lanctôt KL: see Rojas-Fernandez CH, et al, 74
Langley KA: see Brandl KM, et al, 431
Lapane KL: see VanHaaren AM, et al, 1159
Lapointe M: see Haase KK, et al, 103
LaPointe M: see Page RL II, et al, 1436
Larsen JS: Do Antihistamines Have a Role in Asthma Therapy, 28S
Lau TTY, Zed PJ: Does Ketamine Have a Role in Managing Severe Exacerbation of Asthma in Adults, 1100
Lawson CL: see Kockler DR, et al, 647
Lee CR, Thrasher KA: Difficulties in Anticoagulation Management during Coadministration of Warfarin and Rifampin, 1240
Lee HC: see Hoehns JD, et al, 871
Lefkowitz JB: see Sherman DS, et al, 1167
Lenz TL, Wurdeman RL, Hilleman DE: Comparison of 24-Hour Blood Pressure Profiles in Patients with Hypertension Who Were Switched from Amlodipine to Nisoldipine, 898
Lenz TL: see Hilleman DE, et al, 410
Lesur O: see Lamarre P, et al, 506
Levine M, Ensom MHH: Post Hoc Power Analysis: An Idea Whose Time Has Passed, 405

Levine MAH: see Ferko N, et al, 1574
Levy H: see Brandl KM, et al, 431
Lewis JS II: see Nathisuwan S, et al, 920
Lewis P: see Spinler SA, et al, 363
Lewis RE, Kontoyiannis DP: Rationale for Combination Antifungal Therapy, 149S
Li J: see Nicolau DP, et al, 275
Li Z, Willke RJ, Pinto LA, Rittenhouse BE, Rybak MJ, Pleil AM, Crouch CW, Hafkin B, Glick HA: Comparison of Length of Hospital Stay for Patients with Known or Suspected Methicillin-Resistant *Staphylococcus* Species Infections Treated with Linezolid or Vancomycin: A Randomized, Multicenter Trial, 263
Liao L: see Nashed MH, et al, 502
Lile J: Low-Molecular-Weight Heparin Administration in Patients with End-Stage Renal Disease—A Comment, 1017
Linden PK, Bompart F, Gray S, Talbot GH: Hyperbilirubinemia during Quinupristin-Dalfopristin Therapy in Liver Transplant Recipients: Correlation with Available Liver Biopsy Results, 661
Lindenfeld J: see Sherman DS, et al, 1167
Liu H: see Korth-Bradley JM, et al, 1175
Locke C: see Ravnan SL, et al, 884
Lockheart MSK: see St. Peter JV, et al, 183
Longe RL: see Taylor AT, et al, 189
Longstreth J: see Davies NM, et al, 60
Lopez L: see Stringer KA, et al, 1317
Lopez LM: Low-Molecular-Weight Heparins Are Essentially the Same for Treatment and Prevention of Venous Thromboembolism, 56S
Lott RS, Helmboldt KM, Madaras-Kelly KJ: Retrospective Evaluation of the Effect of Valproate Therapy on Transaminase Elevations in Patients with Hepatitis C, 1345
Lowenthal SP: see Taylor AJ, et al, 1130
Lugo RA, MacLaren R, Cash J, Pribble CG, Vernon DD: Enteral Methadone to Expedite Fentanyl Discontinuation and Prevent Opioid Abstinence Syndrome in the PICU, 1566
Lund BC, Neiman RF: Visual Disturbance Associated with Celecoxib, 114
Lund BC: see Carnahan RM, et al, 717
Lund BC: see Hatch CD, et al, 1003

- M -

MacKnight C: see Rojas-Fernandez CH, et al, 74
MacLaren R, Wilson SJ, Campbell A, Anderson D, Rocker G: Evaluation and Survey of Intravenous Vitamin K1 for Treatment of Coagulopathy in Critically Ill Patients, 175
MacLaren R: see Lugo RA, et al, 1566
Madaras-Kelly KJ: see Lott RS, et al, 1345
Maine LL: see Gans JA, et al, 120
Malone DC: see Okano GJ, et al, 1123
Manasse HR, Zellmer WA: American Society of Health-System Pharmacists View on ACCP Manpower White Paper, 123
Maneval K: see Taylor AJ, et al, 1130
Mangum EM, Graham KK: Lopinavir-Ritonavir: A New Protease Inhibitor, 1352
Mashni JE: see Hilleman DE, et al, 1415
Masih M: see Jafari M, et al, 1403
Mason B: see Okano GJ, et al, 1123
Mason RP: Mechanisms of Plaque Stabilization for a Charged Calcium Channel Blocker in Coronary Artery Disease, 209S
Matheny CJ, Lamb MW, Brouwer KLR, Pollack GM: Pharmacokinetic and Pharmacodynamic Implications of P-glycoprotein Modulation, 778
Mathis AS, Meswani P, Spinler SA: Risk Stratification in Non-ST Segment Elevation Acute Coronary Syndromes with Special Focus on Recent Guidelines, 954
Mathur S: see Smith AL, et al, 764
Maxwell R: see Conley EL, et al, 1325
McCarthy MW: see Kockler DR, et al, 647
McElnay JC: see Cordina M, et al, 1196
McGriff NJ, Csako G, Kabbani M, Diep L, Chrousos GP, Pucino F: Treatment Options for a Patient Experiencing Pruritic Rash Associated with Transdermal Testosterone: A Review of the Literature, 1425
McKinlay JB: see Derby CA, et al, 676
McKinnon PS: see Jellison TK, et al, 142
McLendon BM: see Seaburg HL, et al, 1448
McNabb JJ, Nightingale CH, Quintiliani R, Nicolau DP: Cost-Effectiveness of Ceftazidime by Continuous Infusion versus Intermittent Infusion for Nosocomial Pneumonia, 549
McNamara PJ: see Gerk PM, et al, 669
Meadows SL: see Giles JT, et al, 243
Meswani P: see Mathis AS, et al, 954
Meyer LP: see Birner AM, et al, 258
Migden H: see Van Amburgh JA, et al, 1115
Milavetz G: see Asmus MJ, et al, 534
Milkovich G: Intravenous-to-Oral Transition Therapy in Community-Acquired Pneumonia: The INOVA Health System Experience, 83S
Miller LG, Hume A, Harris IM, Jackson EA, Kanmaz TJ, Cauffield JS, Chin TWF, Knell M: Adulteration: Its Various Meanings, 770
Miller RR: A New Journal (reprinted from Volume 1, Number 1), 1157
Miller SM: see Greenberg LE, et al, 1007
Miller WA: The Value and Influence of *Pharmacotherapy* to the Advancement of Clinical Pharmacology and Pharmacotherapy, 1153
Mitchell TM: see Tran MT, et al, 797
Moed B: see Devlin JW, et al, 740
Mohsen A: see Bowles TM, et al, 254
Moles JK: see Kim KY, et al, 498
Monaghan MS: see Hilleman DE, et al, 1415
Moore KHP: see Stein DS, et al, 11
Mooss AN: see Faulkner MA, et al, 1055
Moran GJ: New Directions in Antiinfective Therapy for Community-Acquired Pneumonia in the Emergency Department, 95S
Muggia V: see Garey KW, et al, 748

Murdoch RD: see Zussman BD, et al, 653
Mylotarg Study Group: see Korth-Bradley JM, et al, 1175

- N -

Nabulsi S: see Ritter JL, et al, 1145
Nafziger AN: see Streetman DS, et al, 443
Nahata MC: see Temple ME, et al, 287
Nahata MC: see Temple ME, et al, 351
Nakahiro RK: see Okamoto MP, et al, 1337
Nalysnyk L: see Ross SD, et al, 940
Nappi JM: see Wiggins BS, et al, 320
Nashed MH, Liao L: Possible Atypical Cross-Sensitivity between Phenytoin and Carbamazepine in the Anticonvulsant Hypersensitivity Syndrome, 502
Nathisuwan S, Burgess DS, Lewis JS II: Extended-Spectrum β-Lactamases: Epidemiology, Detection, and Treatment, 920
Neafus KL: see St. Peter JV, et al, 183
Neiman RF: see Lund BC, et al, 114
Neuhauser M: see Rodvold KA, et al, 233S
Neuhauser MM: see Bearden DT, et al, 1204
Nguyen T: see Greenberg LE, et al, 1007
Nicolau DP, Onyeji CO, Banevicius MA, Li J, Nightingale CH: Effects of Adjunctive Treatment with Combined Cytokines in a Neutropenic Mouse Model of Multidrug-Resistant *Enterococcus faecalis* Septicemia, 275
Nicolau DP: see McNabb JJ, et al, 549
Nightingale CH: see McNabb JJ, et al, 549
Nightingale CH: see Nicolau DP, et al, 275
Nix DE: see Zhu M, et al, 891
North DS: see Fish DN, et al, 35
Noviasky JA, Gaffney BJ: The "Superiority" of Enoxaparin for Treatment of Acute Coronary Syndromes, 1250
Nutescu E: see Duplaga BA, et al, 218

- O -

O'Connell MB: see Willhite LA, et al, 464
O'Malley PG: see Taylor AJ, et al, 1130
Okamoto MP, Nakahiro RK: Pharmacoeconomic Evaluation of a Pharmacist-Managed Hypertension Clinic, 1337
Okano GJ, Malone DC, Billups SJ, Carter BL, Sintek CD, Covey D, Mason B, Jue S, Carmichael J, Guthrie K, Dombrowski R, Geraets DR, Amato MG: Reduced Quality of Life in Veterans at Risk for Drug-Related Problems, 1123
Olson KL, Bungard TJ, Tsuyuki RT: Cholesterol Risk Management: A Systematic Examination of the Gap from Evidence to Practice, 807
Onyeji CO: see Nicolau DP, et al, 275
Orsi A, Sherman O, Woldeselassie Z: Simvastatin-Associated Memory Loss, 767
Osterhaus JT: see Ernst ME, et al, 988
Osterhaus MC: see Ernst ME, et al, 988
Owens RC: Risk Assessment for Antimicrobial Agent-Induced QTc Interval Prolongation and Torsades de Pointes, 301

- P -

Page RL II, Ruscin JM, Fish D, LaPointe M: Possible Interaction Between Intravenous Azithromycin and Oral Cyclosporine, 1436
Parier JL: see Zhao Q, et al, 149
Pasquier O: see Garey KW, et al, 748
Patel P: see Sherman J, et al, 1464
Patrick KL: see Armstrong EP, et al, 345
Patterson BD: see Chapman SA, et al, 1549
Pellock JM: Important Changes in the Treatment of Epilepsy, 517
Peloquin CA: see Zhu M, et al, 1037
Peloquin CA: see Zhu M, et al, 891
Pendland SL: see Garey KW, et al, 855
Perreault B: see Lamarre P, et al, 506
Perry PJ: see Carnahan RM, et al, 717
Perry PJ: see Hatch CD, et al, 1003
Pesco-Koplowitz L: see Zhao Q, et al, 149
Pfaller MA: see Hoffman HL, et al, 111S
Pham JV, Puzantian T: Ecstasy: Dangers and Controversies, 1561
Piekos KA: see Kanji S, et al, 1389
Pieper JA: Introduction to Pharmacologic Interventions for Coronary Artery Disease and Risk Factors, 189S
Pieper JA: Management of Coronary Heart Disease Risk Factors and Progression with Calcium Channel Blockers, 195S
Pineo GF: New Developments in the Prevention and Treatment of Venous Thromboembolism, 51S
Pinto LA: see Li Z, et al, 263
Piscitelli SC: see Groll AH, et al, 133S
Pleil AM: see Li Z, et al, 263
Pollack GM: see Matheny CJ, et al, 778
Pollock BG: see Conley EL, et al, 1325
Possidente CJ, Howe JG, Cushman M: Evaluation of Very Low-Dose Subcutaneous Vitamin K During Postoperative Warfarin Therapy, 295
Potter D: see Glover ML, et al, 7
Prato BS: see Fraser GL, et al, 1
Press RA: The Use of Fluoroquinolones as Antiinfective Transition-Therapy Agents in Community-Acquired Pneumonia, 100S
Pribble CG: see Lugo RA, et al, 1566
Pucino F: see Kuo GM, et al, 528
Pucino F: see McGriff NJ, et al, 1425
Pugatch D: see Wedekind CA, et al, 861
Pursell KJ: see Garey KW, et al, 855
Puzantian T: see Pham JV, et al, 1561

- Q -

Qualls CR: see Brandl KM, et al, 431
Quinlan J: see Zussman BD, et al, 653
Quintiliani R: Introduction to Optimizing Antiinfective Transition Therapy in Community-Acquired Pneumonia, 77S
Quintiliani R: see McNabb JJ, et al, 549

- R -

Racine E: Differentiation of the Low-Molecular-Weight Heparins, 62S

Racine E: see Kanji S, et al, 1389
Raehl CL: see Bond CA, et al, 1023
Raehl CL: see Bond CA, et al, 129
Raehl CL: see Bond CA, et al, 614
Raffi F: see Crémieux A, et al, 424
Ramirez JA: Managing Antiinfective Therapy of Community-Acquired Pneumonia in the Hospital Setting: Focus on Switch Therapy, 79S
Ramlatchman LV: see Stoner SC, et al, 850
Ransom JL: see Glover ML, et al, 7
Rathbun S: see Havrda DE, et al, 355
Ravnan SL, Locke C: Levofloxacin and Warfarin Interaction, 884
Record KE: see Darkow T, et al, 540
Reddy P: Does Prophylaxis against Atrial Fibrillation after Cardiac Surgery Reduce Length of Stay or Hospital Costs, 338
Redman AR: Implications of Cytochrome P450 2C9 Polymorphism on Warfarin Metabolism and Dosing, 235
Reed E: see Burstein AH, et al, 281
Reichert MG, Verzino KC: Triiodothyronine Supplementation in Patients Undergoing Cardiopulmonary Bypass, 1368
Remmel RP: see Birnbaum AK, et al, 158
Richmond PL: see Goram AL, et al, 751
Riker RR: see Brandl KM, et al, 431
Riker RR: see Fraser GL, et al, 1
Ritchie SY: see Zussman BD, et al, 653
Rittenhouse BE: see Li Z, et al, 263
Ritter JL, Nabulsi S: Fenofibrate-Induced Elevation in Serum Creatinine, 1145
Rivers CW: see Duplaga BA, et al, 218
Robinson CA, Kuhn RJ, Craigmyle LJ, Anstead MI, Kanga JF: Susceptibility of *Pseudomonas aeruginosa* to Cefepime versus Ceftazidime in Patients with Cystic Fibrosis, 1320
Rocker G: see MacLaren R, et al, 175
Rodvold KA, Neuhauser M: Pharmacokinetics and Pharmacodynamics of Fluoroquinolones, 233S
Rodvold KA: Antibiotic Pharmacodynamics: Integration of Science with Therapeutic Decisions, 291S
Rodvold KA: Pharmacodynamics of Antiinfective Therapy: Taking What We Know to the Patient's Bedside, 319S
Rodvold KA: see Garey KW, et al, 748
Rogers PD: see Cleary JD, et al, 1046
Rojas-Fernandez CH, Lanctôt KL, Allen DD, MacKnight C: Pharmacotherapy of Behavioral and Psychological Symptoms of Dementia: Time for a Different Paradigm, 74
Ross GH, Hovde LB, Ibrahim YH, Rotschafer JC: In Vitro Pharmacodynamic Analysis of Single Daily Dosing versus Conventional Dosing of Gentamicin Administered with Penicillin Against *Enterococcus faecalis*, 1479
Ross GH: see Gunderson BW, et al, 302S
Ross SD, Akhras KS, Zhang S, Rozinsky M, Nalysnyk L: Discontinuation of Antihypertensive Drugs Due to Adverse Events: A Systematic Review and Meta-analysis, 940
Roth MT, Westman EC: Use of Bupropion SR in a Pharmacist-Managed Outpatient Smoking-Cessation Program, 636
Rotschafer JC: see Gunderson BW, et al, 302S
Rotschafer JC: see Ross GH, et al, 1479
Rozinsky M: see Ross SD, et al, 940
Rubino CM: see Glover ML, et al, 7
Ruscin JM: see Page RL II, et al, 1436
Rybak MJ: see Jellison TK, et al, 142
Rybak MJ: see Li Z, et al, 263
Rybak MJ: see Rybak MJ, et al, 998
Rybak MJ: see Tillotson GS, et al, 358

- S -

Schachtner JM: see Smith AL, et al, 764
Scheid D: see Havrda DE, et al, 355
Schoen MD, DiDomenico RJ, Connor SE, Dischler JE, Bauman JL: Impact of the Cost of Prescription Drugs on Clinical Outcomes in Indigent Patients with Heart Disease, 1455
Schoening S: see Glover ML, et al, 7
Schofield JP: see Zussman BD, et al, 653
Seaburg HL, McLendon BM, Doraiswamy PM: Olanzapine-Associated Severe Hyperglycemia, Ketonuria, and Acidosis: Case Report and Review of Literature, 1448
Semchuk W: see Simpson SH, et al, 731
Sen S: see Carlson MK, et al, 108
Seta ML, Kale-Pradhan PB: Efficacy of Metoclopramide in Postoperative Ileus after Exploratory Laparotomy, 1181
Shaffer CL: see Glover ML, et al, 7
Sheikh M: see Taylor AJ, et al, 1130
Sherman DS, Clarke SH, Lefkowitz JB, Valuck RJ, Lindenfeld J, Stringer KA: An Institution-Specific Heparin Titration Nomogram: Development, Validation, and Assessment of Compliance, 1167
Sherman J, Patel P, Hutson A, Chesrown S, Hendeles L: Adherence to Oral Montelukast and Inhaled Fluticasone in Children with Persistent Asthma, 1464
Sherman O: see Orsi A, et al, 767
Simpson SH, Johnson JA, Biggs C, Biggs RS, Kuntz A, Semchuk W, Taylor JG, Farris KB, Tsuyuki RT: Practice-Based Research: Lessons from Community Pharmacist Participants, 731
Simpson SH, Johnson JA, Tsuyuki RT: Economic Impact of Community Pharmacist Intervention in Cholesterol Risk Management: An Evaluation of the Study of Cardiovascular Risk Intervention by Pharmacists, 627
Sintek CD: see Okano GJ, et al, 1123
Sirmans SM, Beck JK, Banh HL, Freeman DA: Colestipol-Induced Hepatotoxicity, 513
Sitar DS: see Tenenbein PK, et al, 1331
Skelly KS: see Hoehns JD, et al, 871
Smith AL, Haider K, Schachtner JM, Mathur S, VanOrden R, Gentile TC: Fatal Hemolysis After

High-Dose Etoposide: Is Benzyl Alcohol to Blame, 764
Smith AL: see Easton-Carter KL, et al, 867
Smith JC: see Straka RJ, et al, 818
Sommi RW: see Bowles TM, et al, 254
Song J: see Bleske BE, et al, 1187
Song J: see White CM, et al, 773
Song JC: see Ammar R, et al, 437
Sorkness CA: Leukotriene Receptor Antagonists in the Treatment of Asthma, 345
Spain J: see Taylor AJ, et al, 1130
Spencer AP: see Kalus JS, et al, 1015
Spinler SA, Davydov L, Dietz PA, Lewis P, Twichell ML: Activated Partial Thromboplastin Time Evaluation, 363
Spinler SA, Inverso SM: Update on Strategies to Improve Thrombolysis for Acute Myocardial Infarction, 691
Spinler SA: see Inverso SM, et al, 1021
Spinler SA: see Mathis AS, et al, 954
Spruill WJ, Wade WE, Cobb HH III, Akbari S: Three Michaelis-Menten Pharmacokinetic Dosing Methods Compared with Physician Dosing of Phenytoin in an Outpatient Neurology Practice, 1407
Spruill WJ: see Taylor AT, et al, 189
St. Peter JV, Neafus KL, Khan MA, Vessey JT, Lockheart MSK: Factors Associated with the Risk of Liver Enzyme Elevation in Patients with Type 2 Diabetes Treated with a Thiazolidinedione, 183
Stanford RH: see Hoehns JD, et al, 871
Stein DS, Moore KHP: Phosphorylation of Nucleoside Analog Antiretrovirals: A Review for Clinicians, 11
Stohlmeyer LA: see Kraus DM, et al, 416
Stoner SC, Worrel JA, Vlach D, Jones MT, Ramlatchman LV: Retrospective Analysis of Serum Valproate Levels and Need for an Antidepressant Drug, 850
Straka RJ, Taheri R, Cooper SL, Tan AWH, Smith JC: Assessment of Hypercholesterolemia Control in a Managed Care Organization, 818
Streetman DS, Nafziger AN, Destache CJ, Bertino JS Jr: Individualized Pharmacokinetic Monitoring Results in Less Aminoglycoside-Associated Nephrotoxicity and Fewer Associated Costs, 443
Stringer KA, Lopez L, Talbert RL: A Call for Pharmacists to Improve the Care of Patients with Myocardial Infarction, 1317
Stringer KA: see Sherman DS, et al, 1167
Swiecki J: see Taylor AJ, et al, 1130
Sylvia LM, Herbel JL: Manuscript Peer Review—A Guide for Health Care Professionals, 395
Szefler SJ: A Review of Budesonide Inhalation Suspension in the Treatment of Pediatric Asthma, 195

- T -

Taheri R: see Straka RJ, et al, 818
Talbert RL: see Stringer KA, et al, 1317
Talbot GH: see Linden PK, et al, 661
Tam VH: see Rybak MJ, et al, 998
Tan AWH: see Straka RJ, et al, 818
Taylor AJ, Grace K, Swiecki J, Hyatt R, Gibbs H, Sheikh M, O'Malley PG, Lowenthal SP, West M, Spain J, Maneval K, Jones, DL: Lipid-Lowering Efficacy, Safety, and Costs of a Large-Scale Therapeutic Statin Formulary Conversion Program, 1130
Taylor AT, Spruill WJ, Longe RL, Wade WE, Wagner PJ: Improved Health-Related Quality of Life with SSRIs and other Antidepressants, 189
Taylor CT, Donaldson AR: Safety and Effectiveness of Ibutilide in a Community Hospital, 488
Taylor JG: see Simpson SH, et al, 731
Temple ME, Brady MT, Koranyi KI, Nahata MC: Periorbital Cellulitis Secondary to *Conidiobolus incongruus*, 351
Temple ME, Koranyi KI, Nahata MC: The Safety and Antiviral Effect of Protease Inhibitors in Children, 287
Tenenbein M: see Tenenbein PK, et al, 1331
Tenenbein PK, Sitar DS, Tenenbein M: Interaction Between *N*-Acetylcysteine and Activated Charcoal: Implications for the Treatment of Acetaminophen Poisoning, 1331
Teresi ME: see Asmus MJ, et al, 534
Tesoro E: see Garey KW, et al, 748
Teter CJ, Guthrie SK: A Comprehensive Review of MDMA and GHB: Two Common Club Drugs, 1486
Thompson DF, Church CO: Prussian Blue for Treatment of Radiocesium Poisoning, 1364
Thrasher KA: see Lee CR, et al, 1240
Tice AL: see Asmus MJ, et al, 534
Tillotson GS, Rybak MJ: New Milestones Achieved in Fluoroquinolone Safety, 358
Tillotson GS: see Iannini PB, et al, 261
Tillotson GS: see Kuter DJ, et al, 1010
Tompkins AC: see Burstein AH, et al, 281
Townsend RJ: see Ernst ME, et al, 988
Tran MT, Mitchell TM, Kennedy DT, Giles JT: Role of Coenzyme Q_{10} in Chronic Heart Failure, Angina, and Hypertension, 797
Travaglini MT: see Werner AL, et al, 1082
Tsikouris AP: see Tsikouris JP, et al, 207
Tsikouris JP, Cox CD: A Review of Class III Antiarrhythmic Agents for Atrial Fibrillation: Maintenance of Normal Sinus Rhythm, 1514
Tsikouris JP, Tsikouris AP: Review of Available Fibrin-Specific Thrombolytic Agents Used in Acute Myocardial Infarction, 207
Tsikouris JP: see White CM, et al, 773
Tsuyuki RT, Bungard TJ: Poor Adherence with Hypolipidemic Drugs: A Lost Opportunity, 576
Tsuyuki RT: see Olson KL, et al, 807
Tsuyuki RT: see Simpson SH, et al, 627
Tsuyuki RT: see Simpson SH, et al, 731
Twichell ML: see Spinler SA, et al, 363
Tyburski JG: see Devlin JW, et al, 740

- V -

Valuck RJ: see Sherman DS, et al, 1167

Van Amburgh JA, Waite NM, Hobson EH, Migden H: Improved Influenza Vaccination Rates in a Rural Population as a Result of a Pharmacist-Managed Immunization Campaign, 1115
VanHaaren AM, Lapane KL, Hughes CM: Effect of Triplicate Prescription Policy on Benzodiazepine Administration in Nursing Home Residents, 1159
VanOrden R: see Smith AL, et al, 764
Venitz J: see Brophy DF, et al, 169
Venzon D: see Burstein AH, et al, 281
Vernon DD: see Lugo RA, et al, 1566
Verzino KC: see Reichert MG, et al, 1368
Vessey JT: see St. Peter JV, et al, 183
Vlach D: see Stoner SC, et al, 850
Vlasses PH, Wadelin JW: American Council on Pharmaceutical Education View on ACCP Manpower White Paper, 117

- W -

Wacksman GP: see Chapman SA, et al, 1549
Wade WE: see Spruill WJ, et al, 1407
Wade WE: see Taylor AT, et al, 189
Wadelin JW: see Vlasses PH, et al, 117
Wagner PJ: see Taylor AT, et al, 189
Waite NM: see Van Amburgh JA, et al, 1115
Wallace WL: see Giles JT, et al, 243
Walls C: see Zussman BD, et al, 653
Walsh TJ: see Groll AH, et al, 133S
Wazny LD: see Brophy DF, et al, 169
Webber D: see Zussman BD, et al, 653
Wedekind CA, Pugatch D: Lipodystrophy Syndrome in Children Infected with Human Immunodeficiency Virus, 861
Wells BG, Bertin RJ: Board of Pharmaceutical Specialties View on ACCP Manpower White Paper, 126
Werner AL, Travaglini MT: A Review of Rosiglitazone in Type 2 Diabetes Mellitus, 1082
West M: see Taylor AJ, et al, 1130
Westman EC: see Roth MT, et al, 636
White CM, Fan C, Song J, Tsikouris JP, Chow M: An Evaluation of the Hemostatic Effects of Hydrophilic, Alcohol, and Lipophilic Extracts of Notoginseng, 773
White CM: see Ammar R, et al, 437
White CM: see Bleske BE, et al, 1187
White CM: see Caron MF, et al, 481
White RL: What In Vitro Models of Infection Can and Cannot Do, 292S
Wiggins BS, Wittkowsky AK, Nappi JM: Clinical Use of New Antithrombotic Therapies for Medical Management of Acute Coronary Syndromes, 320
Wilkins ML: see Fraser GL, et al, 1
Willhite LA, O'Connell MB: Urogenital Atrophy: Prevention and Treatment, 464
Williams DM: Clinical Considerations in the Use of Inhaled Corticosteroids for Asthma, 38S
Willke RJ: see Li Z, et al, 263
Wilson SJ: see MacLaren R, et al, 175
Wittkowsky AK: see Wiggins BS, et al, 320
Wojcik MA: see Zhao Q, et al, 149
Woldeselassie Z: see Orsi A, et al, 767
Wong-Beringer A: Therapeutic Challenges Associated with Extended-Spectrum, β-Lactamase-Producing *Escherichia coli* and *Klebsiella pneumoniae*, 583
Woolley K: see Hilleman DE, et al, 1415
Worrel JA: see Stoner SC, et al, 850
Wurdeman RL: see Hilleman DE, et al, 410
Wurdeman RL: see Lenz TL, et al, 898

- Y, Z -

Yarboro C: see Kuo GM, et al, 528
Yuen GJ: see Crémieux A, et al, 424
Zambie MF: see Henann NE, et al, 1579
Zaw W, Knoppert DC, da Silva O: Flumazenil's Reversal of Myoclonic-like Movements Associated with Midazolam in Term Newborns, 642
Zed PJ: see Lau TTY, et al, 1100
Zellmer WA: see Manasse HR, et al, 123
Zhang S: see Ross SD, et al, 940
Zhao Q, Wojcik MA, Parier JL, Pesco-Koplowitz L: Influence of Coadministration of Fluoxetine on Cisapride Pharmacokinetics and QTc Intervals in Healthy Volunteers, 149
Zhu M, Burman WJ, Jaresko GS, Berning SE, Jelliffe RW, Peloquin CA: Population Pharmacokinetics of Intravenous and Intramuscular Streptomycin in Patients with Tuberculosis, 1037
Zhu M, Nix DE, Adam RD, Childs JM, Peloquin CA: Pharmacokinetics of Cycloserine under Fasting Conditions and with High-Fat Meal, Orange Juice, and Antacids, 891
Zussman BD, Davie CC, Kelly J, Murdoch RD, Clark DJ, Schofield JP, Walls C, Birrell C, Webber D, Quinlan J, Ritchie SY, Carr A: Bioavailability of the Oral Selective Phosphodiesterase 4 Inhibitor Cilomilast, 653

Index to Volume 21

Subject Index

- A -

Abacavir, lamivudine, and zidovudine, a comparison of the steady-state pharmacokinetics and safety of, taken as a triple combination tablet and as abacavir plus a lamivudine-zidovudine double combination tablet by HIV-1-infected adults, 424

ACCP 2001 annual meeting, abstracts and index of authors, 1253

ACCP white paper: manpower, introduction to commentaries, 116

ACCP white paper: manpower, view of Board of Pharmaceutical Specialties, 126

ACCP white paper: manpower, view of the American Council on Pharmaceutical Education, 117

ACCP white paper: manpower, view of the American Pharmaceutical Association, 120

ACCP white paper: manpower, view of the American Society of Health-System Pharmacists, 123

ACCP, 2001 spring practice and research forum, abstracts and index of authors, 365

Acetaminophen poisoning, interaction between *N*-acetylcysteine and activated charcoal: implications for the treatment of, 1331

Acidosis, hyperglycemia, and ketonuria, olanzapine-associated severe, case report and review of literature, 1448

Acinetobacter baumannii bacteremia treated with imipenem-cilastatin or ampicillin-sulbactam, epidemiology, resistance, and outcomes of, 142

Activated charcoal, interaction between *N*-acetylcysteine and: implications for the treatment of acetaminophen poisoning, 1331

Activated partial thromboplastin time evaluation, 363

Acute coronary syndrome, potential influence of timing of low-density lipoprotein cholesterol evaluation in patients with, 1055

Acute coronary syndromes, clinical use of new antithrombotic therapies for medical management of, 320

Acute coronary syndromes, risk stratification in non-ST segment elevation with special focus on recent guidelines, 954

Acute coronary syndromes, the "superiority" of enoxaparin for treatment of, 1250

Acute myocardial infarction, update on strategies to improve thrombolysis for, 691

Adulteration: its various meanings, 770

Adverse drug events, fatal, can the frequency and risks be determined, 521

Aggressive behavior in patients with dementia after head injury, selective serotonin reuptake inhibitors for, 498

Alcohol and gamma-hydroxybutyrate, successful management of prolonged withdrawal, 254

Allopurinol-induced aseptic meningitis, suspected, 1007

Aminoglycoside-associated nephrotoxicity, pharmacokinetic monitoring results in less, and fewer associated costs, 443

Amlodipine to nisoldipine, comparison of 24-hour blood pressure profiles in patients with hypertension who were switched from, 898

Amphotericin B formulations, lipid-based, a prospective and retrospective analysis of the nephrotoxicity and efficacy of, 1107

Amphotericin B, differential transcription factor expression in human mononuclear cells in response to: identification with complementary DNA microarray technology, 1046

Ampicillin-sulbactam or imipenem-cilastatin, epidemiology, resistance, and outcomes of *Acinetobacter baumannii* bacteremia treated with, 142

Angina, chronic heart failure, and hypertension, role of coenzyme Q_{10} in, 797

Angiotensin-converting enzyme inhibitors and aspirin, quantifying the interaction between: are we using the right method, 1247

Antiarrhythmic therapy in patients at risk for sudden cardiac death, role of, an evidence-based review, 556

Antibiotic-induced cardiac toxicity, evaluating the risk of, 261

Anticonvulsant hypersensitivity syndrome, possible atypical cross-sensitivity between phenytoin and carbamazepine in the, 502

Antidepressant drug, retrospective analysis of serum valproate levels and need for, 850

Antidepressants and SSRIs, improved health-related quality of life with, 189

Antiemetic selection, impact of, on postoperative nausea and vomiting and patient satisfaction, 540

Antifungal agents, investigational, 165s

Antifungal pharmacodynamics: concentration-effect relationships in vitro and in vivo, 133s

Antifungal resistance among *Candida* species, 124s

Antifungal susceptibility testing, in vitro, 111s

Antifungal therapy, rationale for combination, 149s

Antihistamines, do they have a role in asthma therapy, 28s

Antihyperlipidemic properties of dietary supplements, evaluation of the, 481

Antihypertensive drugs, discontinuation of, due to adverse events: a systematic review and meta-analysis, 940

Antimicrobial chemotherapy in clinical practice, abstracts of the 2nd international meeting, (volume 21, number 11, part 3), 331s
Antimicrobials, hematologic effects of: focus on the oxazolidinone linezolid, 1010
Antiretrovirals, phosphorylation of nucleoside analog, a review for clinicians, 11
Antithrombotic agents for secondary prevention of cardioembolic and noncardioembolic stroke—another viewpoint, 1021
Antithrombotic drugs for secondary stroke prophylaxis, 452
Antithrombotic drugs for secondary stroke prophylaxis—a comment, 1020
Antithrombotic therapies, clinical use of new, for medical management of acute coronary syndromes, 320
Aseptic meningitis after intraventricular administration of gentamicin, 103
Aspirin and angiotensin-converting enzyme inhibitors, quantifying the interaction between: are we using the right method, 1247
Asthma in adults, does ketamine have a role in managing severe exacerbation of, 1100
Asthma therapy, do antihistamines have a role in, 28s
Asthma, a review of budesonide inhalation suspension in the treatment of pediatric, 195
Asthma, adherence to oral montelukast and inhaled fluticasone in children with persistent, 1464
Asthma, assessment of a community pharmacy-based program for patients with, 1196
Asthma, clinical considerations in the use of inhaled corticosteroids for, 38s
Asthma, drug treatment of airway inflammation in, 3s
Asthma, leukotriene receptor antagonists in the treatment of, 34s
Atrial fibrillation after cardiac surgery, does prophylaxis against reduce length of stay or hospital costs, 338
Atrial fibrillation, a review of class III antiarrhythmic agents for, maintenance of normal sinus rhythm, 1514
Azathioprine, warfarin resistance due to, 355
Azithromycin, intravenous, and oral cyclosporine, possible interaction between, 1436

- B -

Behavioral and psychological symptoms of dementia, pharmacotherapy of, time for a different paradigm? 74
Benzodiazepine administration in nursing home residents, effect of triplicate prescription policy on, 1159
Benzyl alcohol, as a cause of fatal hemolysis after high-dose etoposide, 764
Beta-agonists, single-isomer, 21s
Beta-lactamase-producing *Escherichia coli* and *Klebsiella pneumoniae*, therapeutic challenges associated with, 583
Beta-lactamases, extended-spectrum: epidemiology, detection, and treatment, 920
Boldo-fenugreek and warfarin, potential interaction between, 509
Bone marrow transplant patient, *Cunninghamella bertholletiae* infection in a, amphotericin lung penetration, MIC determinations, and review of the literature, 855
Breast cancer risk-assessment and education program, results of a community pharmacy-based, 243
Budesonide inhalation suspension, a review of, in the treatment of pediatric asthma, 195
Bupropion SR, use of, in a pharmacist-managed outpatient smoking-cessation program, 636

- C -

Caffeine, evaluation of electrocardiographic and hemodynamic effects of, with acute dosing in healthy volunteers, 437
Calcium channel blocker, mechanisms of plaque stabilization for a charged, in coronary artery disease, 216s
Calcium channel blockers, management of coronary heart disease risk factors and progression with, 195s
Candida species, antifungal resistance among, 124s
Carbamazepine and phenytoin, possible atypical cross-sensitivity between in the anticonvulsant hypersensitivity syndrome, 502
Cardiac arrest, hematologic and chemical changes observed during and after, in a canine model—a pilot study, 1187
Cardiac toxicity, antibiotic-induced, evaluating the risk of, 261
Cardiopulmonary bypass, triiodothyronine supplementation in patients undergoing, 1368
Cefepime versus ceftazidime, susceptibility of *Pseudomonas aeruginosa* to, in patients with cystic fibrosis, 1320
Ceftazidime by continuous infusion versus intermittent infusion for nosocomial pneumonia, cost-effectiveness of, 549
Ceftazidime versus cefepime, susceptibility of *Pseudomonas aeruginosa* to, in patients with cystic fibrosis, 1320
Celecoxib, visual disturbance associated with, 114
Celecoxib, visual disturbance associated with: a comment, 1014
Cerebrospinal fluid concentrations of quinupristin-dalfopristin in a patient with vancomycin-resistant *Enterococcus faecium* ventriculitis, 748
Cesium (radioactive) poisoning, Prussian blue for treatment of, 1364
Chlorpromazine, torsades de pointes associated with, case report and review of associated ventricular arrhythmias, 871
Cholesterol and glycemic effects of niaspan in patients with type 2 diabetes, 1473
Cholesterol risk management, economic impact of community pharmacist intervention in, 627
Cholesterol risk management: a systematic examination of the gap from evidence to practice, 807

Cholesterol, potential influence of timing of low-density lipoprotein, evaluation in patients with acute coronary syndrome, 1055
Chronic heart failure, angina, and hypertension, role of coenzyme Q_{10} in, 797
Chronic heart failure, metoprolol CR/XL in the treatment of, 604
Chronic obstructive pulmonary disease, management of acute exacerbations of, 929
Cilomilast, bioavailability of the oral selective phosphodiesterase 4 inhibitor, 653
Ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin, rates of torsades de pointes associated with, 1468
Cisapride pharmacokinetics, influence of coadministration of fluoxetine on, and QTc intervals in healthy volunteers, 149
Citalopram, lack of effect of a single dose of ketoconazole, on the pharmacokinetics of, 163
Clinical pharmacy services and staffing, summary and recommendations for, and interrelationships among mortality rates, drug costs, total cost of care, and length of stay in United States Hospitals, 129
Club drugs, a comprehensive review of MDMA and GHB, 1486
Coenzyme Q_{10}, role of, in chronic heart failure, angina, and hypertension, 797
Colestipol-induced hepatotoxicity, 513
Community-acquired pneumonia in the hospital setting, managing antiinfective therapy of, focus on switch therapy, 79s
Community-acquired pneumonia, a controlled trial of a critical pathway for treating: the Capital Study, 89s
Community-acquired pneumonia, intravenous-to-oral transition therapy in, the INOVA Health System experience, 83s
Community-acquired pneumonia, new directions in antiinfective therapy for, in the emergency department, 95s
Community-acquired pneumonia, the use of fluoroquinolones as antiinfective transition-therapy agents in, 100s
Compliance with hypolipidemic drugs: a lost opportunity, 576
Conidiobolus incongruus, periorbital cellulitis secondary to, 351
COPD, management of acute exacerbations of, 929
Coronary artery disease, mechanisms of plaque stabilization for a charged calcium channel blocker in, 216s
Coronary disease, markers for progression of, 190s
Coronary heart disease, management of risk factors and progression with calcium channel blockers, 195s
Corticosteroids, clinical considerations in the use of inhaled, for asthma, 38s
Cost of prescription drugs, impact of the, on clinical outcomes in indigent patients with heart disease, 1455
Coxibs, clinical implications of drug interactions with, 1223
Cunninghamella bertholletiae infection in a bone marrow transplant patient: amphotericin lung penetration, MIC determinations, and review of the literature, 855
Cycloserine, pharmacokinetics of, under fasting conditions and with high-fat meal, orange juice, and antacids, 891
Cystic fibrosis pulmonary disease, inflammation and, 593
Cystic fibrosis, susceptibility of *Pseudomonas aeruginosa* to cefepime versus ceftazidime in patients with, 1320
Cytochrome P450 2C9 polymorphism, implications of, on warfarin metabolism and dosing, 235
Cytokines, effects of adjunctive treatment with combined, in a neutropenic mouse model of multidrug-resistant *Enterococcus faecalis* septicemia, 275

- D -

Deep vein thrombosis prophylaxis after major trauma, implementation and evaluation of guidelines for use of enoxaparin in, 740
Dementia, patients with, after head injury, selective serotonin reuptake inhibitors for aggressive behavior, 498
Dementia, pharmacotherapy of behavioral and psychological symptoms of: time for a different paradigm? 74
Device removal in the ICU, the frequency and cost of patient-initiated, 1
Diabetes mellitus, dramatic worsening of type 2, due to olanzapine after 3 years of therapy, 1444
Diabetes, cholesterol and glycemic effects of niaspan in patients with type 2, 1473
Diarrhea, metformin as a cause of late-onset chronic, 1422
Dietary supplements, evaluation of the antihyperlipidemic properties of, 481
Dispensing errors, pharmacists' assessment of, risk factors, practice sites, professional functions, and satisfaction, 614
Doxorubicin, pegylated liposomal, tolerability and toxicity, 751
Drotrecogin alfa (activated), recombinant human activated protein C: a novel therapy for severe sepsis, 1389

- E -

Ecstasy: dangers and controversies, 1561
Elevated thyroid-stimulating hormone and St. John's Wort, evaluation of the association between, 1574
Emergency department, new directions in antiinfective therapy for community-acquired pneumonia in the, 95s
Enoxaparin as deep vein thrombosis prophylaxis after major trauma, implementation and evaluation of guidelines for use of, 740
Enoxaparin should be used cautiously in patients with end-stage renal disease, 1015

Enoxaparin, elevation of hepatic transaminases after use of, 108
Enoxaparin, the "superiority" of, for treatment of acute coronary syndromes, 1250
Enoxaparin, the pharmacokinetics of subcutaneous, in end-stage renal disease, 169
Enterococcus faecalis, in vitro pharmacodynamic analysis of single daily dosing versus conventional dosing of gentamicin administered with penicillin against, 1479
Epilepsy, important changes in the treatment of, 517
Epilepsy, oxcarbazepine in the treatment of, 904
Erectile dysfunction, drug therapy and prevalence of, in the Massachusetts male aging study cohort, 676
Etoposide, fatal hemolysis after high-dose: is benzyl alcohol to blame?, 764
Extended-spectrum beta-lactamases: epidemiology, detection, and treatment, 920
Extended-spectrum, beta-lactamase-producing *Escherichia coli* and *Klebsiella pneumoniae*, therapeutic challenges associated with, 583

- F -

Fenofibrate and warfarin interaction, 886
Fenofibrate-induced elevation in serum creatinine, 1143
Fentanyl discontinuation, enteral methadone to expedite, and prevent opioid abstinence syndrome in the PICU, 1566
Fludarabine pharmacokinetics after subcutaneous and intravenous administration in patients with lupus nephritis, 528
Flumazenil's reversal of myoclonic-like movements associated with midazolam in term newborns, 642
Fluoroquinolone adverse effects and drug interactions, 253s
Fluoroquinolone safety, new milestones achieved in, 358
Fluoroquinolones, integrating them into the hospital formulary, 273s
Fluoroquinolones, mechanism of action of and resistance to, 224s
Fluoroquinolones, pharmacokinetics and pharmacodynamics of, 233s
Fluoroquinolones, the use of, as antiinfective transition-therapy agents in community-acquired pneumonia, 100s
Fluorouracil, prochlorperazine, and topical tretinoin, photosensitivity associated with, 258
Fluoxetine, influence of coadministration of, on pharmacokinetics and QTc intervals in healthy volunteers, receiving cisapride, 149
Fluticasone, adherence to oral montelukast and inhaled, in children with persistent asthma, 1464
Fungal infections, a clinical perspective for the management of invasive: focus on IDSA guidelines, 175s

- G -

Gamma-hydroxybutyrate and alcohol withdrawal, successful management of prolonged, 254
Gatifloxacin, an advanced 8-methoxy fluoroquinolone, 35
Gatifloxacin, ciprofloxacin, ofloxacin, levofloxacin, and moxifloxacin, rates of torsades de pointes associated with, 1468
Gatifloxacin-associated acute hepatitis, 1579
Gatifloxacin-induced QTc prolongation and ventricular tachycardia, 361
Gemtuzumab ozogamicin, impact of age and gender on the pharmacokinetics of, 1175
Gentamicin therapy in the neonatal intensive care unit, a multicenter evaluation of, 7
Gentamicin, aseptic meningitis after intraventricular administration of, 103
Gentamicin, in vitro pharmacodynamic analysis of single daily dosing versus conventional dosing of, administered with penicillin against *Enterococcus faecalis*, 1479
GHB and MDMA, a comprehensive review of, two common club drugs, 1486
Glycemic and cholesterol, effects of niaspan in patients with type 2 diabetes, 1473

- H -

Head injury, selective serotonin reuptake inhibitors for aggressive behavior in patients with dementia after, 498
Heart disease, impact of the cost of prescription drugs on clinical outcomes in indigent patients with, 1455
Hematologic effects of antimicrobials: focus on the oxazolidinone linezolid, 1010
Hemolysis, fatal, after high-dose etoposide: is benzyl alcohol to blame?, 764
Heparin titration nomogram, an institution-specific: development, validation, and assessment of compliance, 1167
Heparin, low-molecular-weight administration in patients with end-stage renal disease—a comment, 1017
Heparins, dosing and monitoring of low-molecular-weight, in special populations, 218
Hepatic failure, possible roxithromycin-induced fulminant, in a child, 867
Hepatic transaminases, elevation of, after enoxaparin use: case report and review of unfractionated and low molecular-weight heparin-induced hepatotoxicity, 108
Hepatitis C, retrospective evaluation of the effect of valproate therapy on transaminase elevations in patients with, 1345
Hepatitis, gatifloxacin-associated acute, 1579
Hepatotoxicity, colestipol-induced 513
HMG-CoA reductase inhibitors in patients with coronary artery disease, therapeutic change of, 410
Human immunodeficiency virus, lipodystrophy syndrome in children infected with, 861
Human immunodeficiency virus, *Rhodococcus equi* pneumonia in a patient with, case report and review, 998

Human milk, active transport of nitrofurantoin into, 669
Hydroxybutyrate, gamma, and alcohol withdrawal, successful management of prolonged, 254
Hydroxycut ingestion, seizure activity and unresponsiveness after, 647
Hyperbilirubinemia during quinupristin-dalfopristin therapy in liver transplant recipients, 661
Hypercholesterolemia control in a managed care organization, assessment of, 818
Hyperglycemia, ketonuria, and acidosis, olanzapine-associated severe, case report and review of literature, 1448
Hypertension clinic, pharmacoeconomic evaluation of a pharmacist-managed, 1337
Hypertension, chronic heart failure, and angina, role of coenzyme Q_{10} in, 797
Hypolipidemic drugs, do they lower medical expenses, 1583
Hypolipidemic drugs, poor adherence with, a lost opportunity, 576

- I, J -

Ibutilide in a community hospital, safety and effectiveness of, 488
Ileus, postoperative, efficacy of metoclopramide in, after exploratory laparotomy, 1181
Imipenem-cilastatin or ampicillin-sulbactam, epidemiology, resistance, and outcomes of *Acinetobacter baumannii* bacteremia treated with, 142
In vitro models of infection, what they can and cannot do, 292s
Inflammation and cystic fibrosis pulmonary disease, 593
Influenza vaccination rates, improved, in a rural population as a result of a pharmacist-managed immunization campaign, 1115
JNC-6, patient-reported adherence to guidelines of the sixth joint national committee on prevention, detection, evaluation, and treatment of high blood pressure, 828
Journal, a new, (reprinted from volume 1, number 1), 1157

- K -

Ketamine, does it have a role in managing severe exacerbation of asthma in adults, 1100
Ketoconazole, lack of effect of a single dose of, on the pharmacokinetics of citalopram, 163
Ketolide, telithromycin: an oral, for respiratory infections, 1204
Ketonuria, hyperglycemia, and acidosis, olanzapine-associated severe, case report and review of literature, 1448

- L -

Lamivudine, abacavir, and zidovudine, a comparison of the steady-state pharmacokinetics and safety of, taken as a triple combination tablet and as abacavir plus a lamivudine-zidovudine double combination tablet by HIV-1-infected adults, 424
Lamotrigine chewable dispersible tablets administered rectally, relative bioavailability of, 158
Leukopenia and SIADH, idiosyncratic rifabutin-induced, 493
Leukotriene receptor antagonists in the treatment of asthma, 34s
Levetiracetam: a novel antiepileptic drug, 1375
Levofloxacin and warfarin interaction, 884
Levofloxacin, ciprofloxacin, ofloxacin, gatifloxacin, and moxifloxacin, rates of torsades de pointes associated with, 1468
Linezolid or vancomycin, comparison of length of hospital stay for patients with known or suspected methicillin-resistant *Staphylococcus* species infections treated with, 263
Linezolid, hematologic effects of antimicrobials: focus on the oxazolidinone, 1010
Lipid screening program, the value of pharmacist involvement in a point-of-care service, walk-in, 1403
Lipodystrophy syndrome in children infected with human immunodeficiency virus, 861
Liver enzyme elevation, factors associated with the risk of, in patients with type 2 diabetes treated with a thiazolidinedione, 183
Lopinavir-ritonavir: a new protease inhibitor, 1364
Lorazepam infusion, short-term, and concern for propylene glycol toxicity: case report and review, 1140
Low-molecular-weight heparins are essentially the same for treatment and prevention of venous thromboembolism, 56s
Low-molecular-weight heparins, differentiation of the, 62s

- M -

MDMA and GHB, a comprehensive review of, two common club drugs, 1486
Medibottle (Rx) versus the oral syringe, effectiveness and infant acceptance of, 416
Medication errors in United States hospitals, 1023
Memory loss, simvastatin-associated, 767
Meningitis, aseptic, after intraventricular administration of gentamicin, 103
Meningitis, suspected allopurinol-induced aseptic, 1007
Metformin as a cause of late-onset chronic diarrhea, 1422
Methadone, enteral, to expedite fentanyl discontinuation and prevent opioid abstinence syndrome in the PICU, 1566
Methicillin-resistant *Staphylococcus* species infections treated with linezolid or vancomycin, comparison of length of hospital stay for patients with known or suspected, 263
Metoclopramide, efficacy of, in postoperative ileus after exploratory laparotomy, 1181
Metoprolol CR/XL in the treatment of chronic heart

failure, 604
Metronidazole, effects of, on hepatic CYP3A4 activity, 1192
Midazolam in term newborns, flumazenil's reversal of myoclonic-like movements associated with, 642
Misoprostol therapeutics revisited, 60
Montelukast, adherence to oral, and inhaled fluticasone in children with persistent asthma, 1464
Moxifloxacin, ciprofloxacin, ofloxacin, levofloxacin, and gatifloxacin, rates of torsades de pointes associated with, 1468
Musculoskeletal disorders, use of point-of-service health status assessments by community pharmacists to identify and resolve drug-related problems in patients with, 988
Myocardial infarction, a call for pharmacists to improve the care of patients with, 1317
Myocardial infarction, a review of available fibrin-specific thrombolytic agents used in acute, 207

- N -

N-acetylcysteine and activated charcoal, interaction between: implications for the treatment of acetaminophen poisoning, 1331
Neonatal intensive care unit, a multicenter evaluation of gentamicin therapy in the, 7
Nephritis, biopsy-proved acute tubulointerstitial, and toxic epidermal necrolysis associated with vancomycin, 1233
Nephrotoxicity and efficacy of lipid-based amphotericin B formulations, a prospective and retrospective analysis of the, 1107
Neuroleptic malignant syndrome with conventional antipsychotics, failed challenge with quetiapine after, 1003
Neutropenia and febrile neutropenia in breast cancer: estimates from two national databases, economic impact of, 684
Niaspan, cholesterol and glycemic effects of, in patients with type 2 diabetes, 1473
Nisoldipine from amlodipine, comparison of 24-hour blood pressure profiles in patients with hypertension who were switched to, 898
Nitrofurantoin, active transport of, into human milk, 669
Nonnicotine pharmacotherapy, effect of, on smoking behavior, 1530
Nosocomial pneumonia, cost-effectiveness of ceftazidime by continuous infusion versus intermittent infusion for, 549
Notoginseng, an evaluation of the hemostatic effects of hydrophilic, alcohol, and lipophilic extracts of, 773
Nucleoside analog antiretrovirals, phosphorylation of, a review for clinicians, 11

- O -

Ofloxacin, ciprofloxacin, levofloxacin, gatifloxacin, and moxifloxacin, rates of torsades de pointes associated with, 1468
Olanzapine, dramatic worsening of type 2 diabetes mellitus due to, after 3 years of therapy, 1444
Olanzapine-associated severe hyperglycemia, ketonuria, and acidosis: case report and review of literature, 1448
Opioid abstinence syndrome in the PICU, enteral methadone to expedite fentanyl discontinuation and prevent, 1566
Oral cyclosporine and intravenous azithromycin, possible interaction between, 1436
Oxcarbazepine in the treatment of epilepsy, 904

- P -

Pain adjunctive agents in the management of chronic, 1070
Pancreatitis associated with valproic acid: a review of the literature, 1549
Pancreatitis-induced systemic inflammatory response syndrome with circulatory shock, vasopressin and blood pressure support for, 506
Partial thromboplastin (activated) time evaluation, 363
Peer review, manuscript, a guide for health care professionals, 395
Pegylated liposomal doxorubicin: tolerability and toxicity, 751
Periorbital cellulitis secondary to *Conidiobolus incongruus*, 351
P-glycoprotein modulation, pharmacokinetic and pharmacodynamic implications of, 778
Pharmacodynamics of antiinfective therapy: taking what we know to the patient's bedside, 319s
Pharmacodynamics, antibiotic: integration of science with therapeutic decisions, 291s
Pharmacodynamics, what do we really know about antibiotic, 302s
Pharmacokinetic monitoring, individualized, results in less aminoglycoside-associated nephrotoxicity and fewer associated costs, 443
Pharmacotherapy, the value and influence of, to the advancement of clinical pharmacology and pharmacotherapy, 1153
Phenylacetate pharmacokinetics based on iterative two-stage population analysis, 281
Phenytoin and carbamazepine, possible atypical cross-sensitivity between, in the anticonvulsant hypersensitivity syndrome, 502
Phenytoin, three Michaelis-Menten pharmacokinetic dosing methods compared with physician dosing of, in an outpatient neurology practice, 1407
Photosensitivity associated with fluorouracil, prochlorperazine, and topical tretinoin, 258
Post hoc power analysis: an idea whose time has passed, 405
Post hoc power analysis—another view, 1150
Power analysis, post hoc, another view, 1150
Power analysis, post hoc: an idea whose time has passed, 405
Practice-based research: lessons from community pharmacist participants, 731

Predictors, prepharmacy, of success in pharmacy school: grade point averages, pharmacy college admissions test, communication abilities, and critical thinking skills, 842
Prochlorperazine, fluorouracil, and topical tretinoin, photosensitivity associated with, 258
Propylene glycol toxicity, short-term lorazepam infusion and concern for, case report and review, 1140
Protease inhibitor, lopinavir-ritonavir: a new, 1364
Protease inhibitors in children, the safety and antiviral effect of, 287
Prussian blue for treatment of radiocesium poisoning, 1364
Pseudomonas aeruginosa, susceptibility of, to cefepime versus ceftazidime in patients with cystic fibrosis, 1320
Psychological and behavioral symptoms of dementia, pharmacotherapy of: time for a different paradigm, 74

- Q -

QTc interval prolongation and torsades de pointes, risk assessment for antimicrobial agent-induced, 301
Quality of life, reduced in veterans at risk for drug-related problems, 1123
Quetiapine, failed challenge with, after neuroleptic malignant syndrome with conventional antipsychotics, 1003
Quinupristin-dalfopristin therapy in liver transplant recipients, hyperbilirubinemia during, 661
Quinupristin-dalfopristin, cerebrospinal fluid concentrations of, in a patient with vancomycin-resistant *Enterococcus faecium* ventriculitis, 748

- R -

Radiocesium poisoning, Prussian blue for treatment of, 1364
Recombinant human activated protein C, drotrecogin alfa (activated): a novel therapy for severe sepsis, 1389
Reductase inhibitors, HMG-CoA, therapeutic change of, in patients with coronary artery disease, 410
Respiratory infections, telithromycin: an oral ketolide for, 1204
Rhodococcus equi pneumonia in a patient with human immunodeficiency virus: case report and review, 998
Rifabutin-induced leukopenia and SIADH, idiosyncratic, 493
Rifampin and warfarin, difficulties in anticoagulation management during coadministration of, 1240
Rosiglitazone, a review of, in type 2 diabetes mellitus, 1082
Roxithromycin-induced fulminant hepatic failure in a child, possible, 867
Rx Medibottle versus the oral syringe, effectiveness and infant acceptance of, 416

- S -

Sedation-agitation scale administered by ICU nurses without experience in its use, confirming the reliability of the, 431
Selective serotonin reuptake inhibitors for aggressive behavior in patients with dementia after head injury, 498
Sepsis, recombinant human activated protein C, drotrecogin alfa (activated): a novel therapy for severe, 1389
SIADH and leukopenia, idiosyncratic rifabutin-induced, 493
Simvastatin-associated memory loss, 767
Skin preparation products, comparison of preoperative, 345
Smoking behavior, effect of nonnicotine pharmacotherapy on, 1530
Smoking-cessation program, use of bupropion SR in a pharmacist-managed outpatient, 636
SSRIs and other antidepressants, improved health-related quality of life with, 189
St. John's Wort and elevated thyroid-stimulating hormone, evaluation of the association between, 1574
Statin formulary conversion program, lipid-lowering efficacy, safety, and costs of a large-scale therapeutic, 1130
Statin therapy intervention, physician-prompting, improves outcomes in patients with coronary heart disease, 1415
Streptomycin, population pharmacokinetics of intravenous and intramuscular, in patients with tuberculosis, 1037
Stroke prophylaxis, antithrombotic drugs for secondary, 452
Substance P: a new era, a new role, 1061
Sudden cardiac death, role of antiarrhythmic therapy in patients at risk for, an evidence-based review, 556
Susceptibility testing, in vitro antifungal, 111s
Switch therapy, managing antiinfective therapy of community-acquired pneumonia in the hospital setting: focus on, 79s

- T -

Telithromycin: an oral ketolide for respiratory infections, 1204
Testosterone, transdermal, treatment options for a patient experiencing pruritic rash associated with, a review of the literature, 1425
Thiazolidinedione, factors associated with the risk of liver enzyme elevation in patients with type 2 diabetes treated with a, 183
Thrombocytopenia with valproic acid, prevalence and risk of: experience at a psychiatric teaching hospital, 1325
Thromboembolism, new developments in the prevention and treatment of venous, 51s
Thromboembolism, venous, low-molecular-weight heparins are essentially the same for treatment and prevention of, 56s
Thrombolysis for acute myocardial infarction, update on strategies to improve, 691

Thrombolytic agents, a review of available fibrin-specific, used in acute myocardial infarction, 207
Tobramycin aerosol from ultrasonic and jet nebulizers, in vitro characteristics of, 534
Torsades de pointes and QTc interval prolongation, risk assessment for antimicrobial agent-induced, 301
Torsades de pointes associated with chlorpromazine: case report and review of associated ventricular arrhythmias, 871
Torsades de pointes, rates of, associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin, 1468
Toxic epidermal necrolysis and acute tubulointerstitial nephritis associated with vancomycin, 1233
Transdermal testosterone, treatment options for a patient experiencing pruritic rash associated with, a review of the literature, 1425
Tretinoin, topical, fluorouracil, and prochlorperazine, photosensitivity associated with, 258
Triiodothyronine supplementation in patients undergoing cardiopulmonary bypass, 1368
Triplicate prescription policy, effect of, on benzodiazepine administration in nursing home residents, 1159
Tuberculosis, population pharmacokinetics of intravenous and intramuscular streptomycin in patients with, 1037
Type 2 diabetes mellitus, a review of rosiglitazone in, 1082

- U, V -

Urogenital atrophy: prevention and treatment, 464
Valproate levels, retrospective analysis of serum, and need for an antidepressant drug, 850
Valproate therapy, retrospective evaluation of the effect of, on transaminase elevations in patients with hepatitis C, 1345
Valproic acid, pancreatitis associated with, a review of the literature, 1549
Valproic acid, prevalence and risk of thrombocytopenia with: experience at a psychiatric teaching hospital, 1325
Vancomycin or linezolid, comparison of length of hospital stay for patients with known or suspected methicillin-resistant *Staphylococcus* species infections treated with, 263
Vancomycin, biopsy-proved acute tubulointerstitial nephritis and toxic epidermal necrolysis associated with, 1233
Vasopressin and blood pressure support for pancreatitis-induced systemic inflammatory response syndrome with circulatory shock, 506
Venous thromboembolism, new developments in the prevention and treatment of, 51s
Ventriculitis, cerebrospinal fluid concentrations of quinupristin-dalfopristin in a patient with vancomycin-resistant *Enterococcus faecium*, 748
Visual disturbance associated with celecoxib, 114
Vitamin K, evaluation and survey of intravenous, for treatment of coagulopathy in critically ill patients, 175
Vitamin K, evaluation of very low-dose subcutaneous, during postoperative warfarin therapy, 295

- W, Z -

Warfarin and boldo-fenugreek, potential interaction between, 509
Warfarin and fenofibrate interaction, 886
Warfarin and levofloxacin interaction, 884
Warfarin and rifampin, difficulties in anticoagulation management during coadministration of, 1240
Warfarin metabolism and dosing, implications of cytochrome P450 2C9 polymorphism on, 235
Warfarin resistance due to azathioprine, 355
Warfarin therapy, evaluation of very low-dose subcutaneous vitamin K during postoperative, 295
Zidovudine, abacavir, and lamivudine, a comparison of the steady-state pharmacokinetics and safety of, taken as a triple combination tablet and as abacavir plus a lamivudine-zidovudine double combination tablet by HIV-1-infected adults, 424
Ziprasidone, a new atypical antipsychotic drug, 717